Home Metabolism ROR

ROR

Isoform-selective Products

ROR Products

  • All (13)
  • ROR Inhibitors (3)
  • ROR Antibodie (1)
  • ROR Agonists (9)
  • New ROR Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of 20nM for LXRα and 5 μM for FXR, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
Front Immunol, 2022, 13:848367
J Anim Sci Biotechnol, 2022, 13(1):120
Commun Biol, 2022, 5(1):132
S5775 SR1078 SR1078, a synthetic ligand for RORα and RORγ, functions as a RORα/γ agonist.
Cell Death Dis, 2021, 12(3):247
S0094 SR 0987 SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.
Evid Based Complement Alternat Med, 2022, 2022:8315503
S3483 TMP778 TMP778 is a selective inhibitor of RORγt with an IC50 of 5 nM in the Fluorescence Resonance Energy Transfer (FRET) assay and an IC50 of 17 nM in the RORγ assay.
S6610 GSK2981278 GSK2981278 is a highly potent and selective inverse agonist for RORγ.
S8860 Cintirorgon (LYC-55716) Cintirorgon (LYC-55716) is a selective, first-in-class, oral, small-molecule investigational agent that selectively activates RORγ.
E0326 S18-000003 S18-000003, a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 μM towards human RORγt in competitive binding assays.
E0637 Cedirogant Cedirogant (ABBV-157) is an orally active RORγt inverse agonist, can be used for psoriasis research.
S6724 SR1001 SR1001 is a RORα inverse agonist with Ki values of 172 nM and 111 nM for RORα and RORγ respectively.
S2654 Neoruscogenin Neoruscogenin, a natural sapogenin isolated from R. rhizoma, is a potent and high-affinity agonist of RAR-related orphan receptor alpha (RORα or nuclear receptor NR1F1).
D4013 Zilovertamab vedotin Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies.
S2969 SR3335 SR3335 (ML-176) is a selective and inverse agonist of retinoic acid receptor-related receptor α (RORα) that directly binds to RORα with Ki of 220 nM.
A2366 Zilovertamab (Anti-ROR1) Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD.
S3483 TMP778 TMP778 is a selective inhibitor of RORγt with an IC50 of 5 nM in the Fluorescence Resonance Energy Transfer (FRET) assay and an IC50 of 17 nM in the RORγ assay.
E0326 S18-000003 S18-000003, a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 μM towards human RORγt in competitive binding assays.
D4013 Zilovertamab vedotin Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies.
A2366 Zilovertamab (Anti-ROR1) Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD.
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of 20nM for LXRα and 5 μM for FXR, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
Front Immunol, 2022, 13:848367
J Anim Sci Biotechnol, 2022, 13(1):120
Commun Biol, 2022, 5(1):132
S5775 SR1078 SR1078, a synthetic ligand for RORα and RORγ, functions as a RORα/γ agonist.
Cell Death Dis, 2021, 12(3):247
S0094 SR 0987 SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.
Evid Based Complement Alternat Med, 2022, 2022:8315503
S6610 GSK2981278 GSK2981278 is a highly potent and selective inverse agonist for RORγ.
S8860 Cintirorgon (LYC-55716) Cintirorgon (LYC-55716) is a selective, first-in-class, oral, small-molecule investigational agent that selectively activates RORγ.
E0637 Cedirogant Cedirogant (ABBV-157) is an orally active RORγt inverse agonist, can be used for psoriasis research.
S6724 SR1001 SR1001 is a RORα inverse agonist with Ki values of 172 nM and 111 nM for RORα and RORγ respectively.
S2654 Neoruscogenin Neoruscogenin, a natural sapogenin isolated from R. rhizoma, is a potent and high-affinity agonist of RAR-related orphan receptor alpha (RORα or nuclear receptor NR1F1).
S2969 SR3335 SR3335 (ML-176) is a selective and inverse agonist of retinoic acid receptor-related receptor α (RORα) that directly binds to RORα with Ki of 220 nM.

Choose Selective ROR Inhibitors

Tags: ROR inhibitor|ROR agonist|ROR activator|ROR inducer|ROR antagonist|ROR signaling pathway|ROR assay kit